Christoph Westphal finds the exit at his latest biotech creation — after the stock cratered
High-profile Boston biotech financier Christoph Westphal is leaving the helm of his latest biotech flop.
A little more than two years after debuting their IPO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
